Changes in biologic characteristics of breast cancer treated with high-intensity focused ultrasound

Ultrasound in Medicine and Biology

Volumn 29, Issue 10, 2003, Pages 1487-1492

  Wu, Feng ^a   Wang, Zhi Biao ^a   Cao, You De ^a   Chen, Wen Zhi ^a   Zou, Jian Zhong ^a   Bai, Jin ^a   Zhu, Hui ^a   Li, Ke Quan ^a   Jin, Cheng Bing ^a   Xie, Fang Lin ^a   Su, Hai Bing ^a   Gao, Gen Wu ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Acoustic surgery; Breast carcinomas; CD44v6; ErbB2, Telomerase activity; Focused ultrasound surgery; High intensity focused ultrasound; MMP 9; PCNA

Indexed keywords

BIOASSAY; BLOOD VESSELS; CELLS; ENZYMES; TUMORS; ULTRASONICS;

BREAST CANCER;

BIOMEDICAL ENGINEERING;

CD44V6 ANTIGEN; CELL ADHESION MOLECULE; CYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GELATINASE B; GLYCOPROTEIN; HERMES ANTIGEN; MESSENGER RNA; MOLECULAR MARKER; RNA; TELOMERASE; TUMOR MARKER; TUMOR PROTEIN;

ANTIGEN DETECTION; ARTICLE; BIOSYNTHESIS; BREAST CARCINOMA; BREAST TUMOR; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MASTECTOMY; METABOLISM; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; TELOMERIC REPEAT AMPLIFICATION PROTOCOL; TREATMENT OUTCOME; ULTRASOUND; ULTRASOUND THERAPY;

EID: 10744231127     PISSN: 03015629     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-5629(03)01034-2     Document Type: Article

References (26)

1. Arriagada R., Le M.G., Rochard F., Contesso G. Conservative treatment versus mastectomy in early breast cancer patterns of failure with 15 years of follow-up data. Institute Gustave-Roussy Breast Cancer Group . J Clin Oncol. 14:1996;1558-1564.
2. Blichert-Toft M., Rose C., Andersen J.A., et al. Danish randomized trial comparing breast conservation therapy with mastectomy Six years of life-table analysis . J Natl Cancer Inst Monogr. 11:1992;19-25.
3. Braun S., Schlimok G., Heumos I., et al. ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage 1-3 breast cancer patients. Cancer Res. 61:2001;1890-1895.
4. Bryan T.M., Englezou A., Gupta J., Bacchetti S., Reddel R.R. Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J. 14:1995;4240-4248.
5. Counter C.M., Hirte H.W., Bacchetti S., Harley C.B. Telomerase activity in human ovarian carcinoma. Proc Natl Acad Sci USA. 91:1994;2900-2904.
6. Curran D., van Dongen J.P., Aronson N.K., et al. Quality of life of early-stage breast cancer patients treated with radical mastectomy or breast-conserving procedure Results of EORTC trial 10801. The European Organization for Research and Treatment of Cancer (EORTC) Breast Cancer Co-operative Group (BCCG) . Eur J Cancer. 34:1998;307-314.
7. Dickson R.B., Lippman M.E. Molecular biology of breast cancer. DeVita V.T., Hellman S., Rosenberg S.A. Cancer principles and practice oncology. 1997;1541-1557 Lippincotth-Raven Publishers, Philadephia.
8. Fisher B., Anderson S., Redmond C.K., et al. Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med. 333:1995;1456-1461.
9. Goldberg G.I., Eisen A.Z. Extracellular matrix metalloproteinase in tumor invasion and metastasis. Cancer Treat Res. 53:1991;421-440.
10. Gupta J., Han L.P., Wang P., Gallie B.L., Bacchetti S. Development of retinoblastoma in the absence of telomerase activity. J Natl Cancer Inst. 88:1996;1152-1157.
11. Jacobson J.A., Danforth D.N., Cowan K.H., et al. Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast cancer. N Engl J Med. 332:1995;907-911.
12. Katoh M., Kameyama M., Kugoh H., Shimizu M., Oshimura M. A repressor function for telomerase activity in telomerase-negative immortal cells. Mol Carcinog. 21:1998;17-25.
13. Kim N.W., Piatyszek M.A., Prowse K.R., et al. Specific association of human telomerase activity with immortal cells and cancer. Science (Washington, DC). 266:1994;2011-2015.
14. Mackay C.R., Terpe H., Stauder R., et al. Expression and modulation of CD44 variant isoforms in humans. J Cell Biol. 124:1994;71-82.
15. Nagase H., Woessner J.F. Jr. Matrix metalloproteinases. J Biol Chem. 274:1999;21491-21494.
16. Parkin D.M., Pisani P., Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer. 53:1993;594-606.
17. Pauletti G., Dandekar S., Rong H.M., et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer A direct comparison of fluorescence in situ hybridization and immunohistochemistry . J Clin Oncol. 18:2000;3651-3664.
18. Rhyu M.S. Telomeres, telomerase, and immortality. J Natl Cancer Inst. 87:1995;884-894.
19. Ross J.S., Fletcher J.A. HER-2/neu (c-erb-B2) gene and protein in breast cancer. Am J Clin Pathol. 112:1999;S53-S67.
20. Salles G., Zain M., Jiang W., Boussiotis V., Shipp M. Alternatively spliced CD44 transcripts in diffuse large cell lymphomas Characterization and comparison with normal activated B cells and epithelial malignancies . Blood. 82:1993;3539-3547.
21. ter Haar G. Acoustic surgery. Phys Today. 54:2001;29-34.
22. van Dongan J.A., Bartelink H., Fentiman I.S., et al. Randomized clinical trial to assess the value of breast-conserving therapy in stage I and II breast cancer, EORTC 10801. J Natl Cancer Inst Monogr. 11:1992;15-18.
23. Veronesi U., Salvadori B., Luini A., et al. Breast conservation is a safe method in patients with small cancer of the breast. Long-term results of three randomised trials on 1, 973 patients. Eur J Cancer. 31A:1995;1574-1579.
24. Wright W.E., Piatyszek M.A., Rainey W.E., Byrd W., Shay J.W. Telomerase activity in human germline and embryonic tissues and cells. Dev Genet. 18:1996;173-179.
25. Wu F., Chen W.Z., Bai J., et al. Pathological changes in human malignant carcinoma treated with high-intensity focused ultrasound. Ultrasound Med Biol. 27:2001;1099-1106.
26. Wu F., Chen W.Z., Bai J., et al. Tumor vessel destruction resulting from high-intensity focused ultrasound in patients with solid malignancies. Ultrasound Med Biol. 28:2002;535-542.